Royalty Report: Medical, Device, Surgical – Collection: 27406

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Medical
  • Device
  • Surgical
  • cardiac
  • Therapeutic
  • Laser
  • Scientific & Technical Instruments
  • Disposable
  • Delivery
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27406

License Grant
The Company, in its acquisition of technology in 1993 related to its TMR therapy from the University.  Under this agreement, the Company has a worldwide exclusive license to any patents that issue in connection related with cardiac revascularization technology for the treatment of advanced cardiovascular disease and severe angina pain through transmyocardial revascularization, TMR.
License Property
TMR is a treatment aimed at improving blood flow to areas of the heart that were not treated by angioplasty or surgery. A special carbon dioxide (CO2) laser is used to create small channels in the heart muscle, improving blood flow in the heart. TMR is a surgical procedure. The procedure is performed through a small left chest incision or through a midline incision. Frequently, it is performed with coronary artery bypass surgery, but occasionally it is performed independently.
Field of Use
Field of use  Medical Industry primarily used by a heart surgeon.

IPSCIO Record ID: 1710

License Grant
The Company hereby grants an exclusive, worldwide right and license, including the right to grant sublicenses, under the Technical Know-How, Licensed Patents and Improvements to practice methods and to manufacture, have manufactured, import, use, offer to sell, sell and otherwise dispose of Licensed Products within the Field of Technology; technology applications relating to the use of lasers to treat cardiovascular or vascular disease.
License Property
Licensed Products shall mean Patented Licensed Products and Unpatented Licensed Products and shall include single use, disposable products as well as the related laser hardware.

Transmyocardial laser revascularization (TMLR) has emerged as a promising therapy for patients with end-stage coronary artery disease not amenable to other forms of therapy. TMLR is a surgical technique typically performed through a left thoracotomy, which uses a laser to bore 15 to 30 transmural channels from the epicardial to the endocardial surfaces through the left ventricular myocardium of the beating heart in an attempt to improve local perfusion to ischemic myocardial territories not being reached by diseased arteries.

Field of Use
Field of Technology  shall mean the use of lasers to treat cardiovascular or vascular disease.

IPSCIO Record ID: 233464

License Grant
Licensor grants a non-exclusive, worldwide license, without the right to sublicense, to make, have made, use, import, sell, offer for sale, or otherwise dispose of Licensed Products, and to practice any method or process involved in the manufacture, testing or use thereof, under the Licensed Licensor Patents.
License Property
Licensor is the exclusive licensee of U.S. Patent No. 4,784,135 and  No. 4,686,979.

The Licensed Products means Lasers, and, Disposables.  Laser shall mean any source of amplified, coherent light having a wavelength between 100 and 400 nanometers.  Disposable shall mean apparatus comprised, at least in part, or one of more optical fibers, that is or may be coupled to a Laser, as hereinafter defined, to guide the light emitted from that Laser to a treatment location within a human or animal body. Such apparatus shall fall within the definition of Disposable irrespective of whether it is intended for use in more than one procedure.

Field of Use
This agreement is for the field of transmyocardial revascularization or percutaneous transmyocardial revascularization.

Transmyocardial laser revascularization (TMR) is a procedure used to treat inoperable heart disease in people with persistent angina that isn't relieved by any other revascularization method.

IPSCIO Record ID: 27347

License Grant
The Company entered into an agreement with an undisclosed Licensor for card-vascular products.
License Property
Bio-Vascular Probe is a flexible shaft with varying sizes of bulbous tips on either end.  Biograft is used to bypass occluded blood vessels and is produced from modified human umbilical veins.
Field of Use
Surgeons use the Bio-Vascular Probe to locate occlusions or blockages in arteries and to ascertain the blood flow characteristics of arteries.

IPSCIO Record ID: 139831

License Grant
The Licensee entered a License Agreement for the reservoir style cardioplegia delivery  systems. The Licensee will pay a royalty to the Licensor, an individual.
License Property
The reservoir style cardioplegia delivery systems encompasses several techniques employed in open-heart surgery to preserve, protect and manage the heart tissue.  Cardioplegia involves the use of a chilled solution which is infused into the heart through the coronary  arteries to cool the heart and reduce heart activity and metabolism.
Field of Use
Cardioplegia is intentional and temporary cessation of cardiac activity, primarily for cardiac surgery.

IPSCIO Record ID: 6931

License Grant
During 2010 we had royalty agreements related to our AtriClip system, which is designed to safely and effectively exclude the left atrial appendage.
License Property
Our AtriClip system is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart, avoiding contact with the circulating blood pool while eliminating blood flow between the left atrial appendage and the atria. We believe that our AtriClip system is potentially safer, more effective and easier to use when permanently excluding the left atrial appendage than current products and techniques.
Field of Use
The rights granted apply to medical devices relating to the healthcare industry.

IPSCIO Record ID: 1098

License Grant
Licensor grants Licensee a non-exclusive, world-wide license under the Licensed Patents to the Licensed Devices for Licensed Applications which would infringe any valid claim of the Licensed Patents.
License Property
Licensor is the owner of U.S. Patent No. 5,037,421 and U.S. Patent No. 5,147,354 both entitled 'Mid Infrared Laser Arthroscopic Procedure'.

LICENSED DELIVERY DEVICE shall mean any device that delivers the laser energy to a desired location which infringes one or more of the valid claims of the Licensed Patents.

Field of Use
LICENSED APPLICATION shall mean only orthopedic applications.

IPSCIO Record ID: 27403

License Grant
The Company owns exclusive, worldwide, perpetual licenses to develop, manufacture and market its Flo-Rester products from an undisclosed Licensor.
License Property
Flo-Rester products are vessel occluders manufactured from medical grade silicone.  The Flo-Rester products are designed to interrupt blood flow in arteries and to stent (hold open) them during surgery, thereby facilitating the suturing together of vessels.  Flo-Rester consists of a flexible shaft with small bulbs at each end that are inserted into the blood vessel at the point where the artery bypass is sutured to the artery to stop the blood flow.

IPSCIO Record ID: 27092

License Grant
The Company hereby grants to Licensee and its Affiliates, upon the terms and subject to the conditions set forth herein, a worldwide, exclusive right and sublicense under USC Patent Rights in the Field of Use.
License Property
Guardian Embolization Protection System patented technology for primary use in the neurointerventional and cardiology markets these markets focus on arteries and veins leading to the brain and those in the heart, and the removal of blockages in these veins and arteries.  The device is designed to prevent deadly embolisms during surgery to clear blocked arteries and prevent strokes and heart attacks.  The key to this device, known as the Guardian System, is a thin string of wire, really a metal tube not much larger in diameter than a human hair, with a marble-sized balloon attached toward the end.
Field of Use
'Field of Use' shall mean diagnostic and/or therapeutic devices used in the treatment or management of patients via the carotid artery or other arteries or veins.

IPSCIO Record ID: 4829

License Grant
In June 1995, the Company entered into a consulting and assignment agreement with an undisclosed surgeon who serves on the Company’s Scientific Advisory Board.
License Property
Under the agreement, the surgeon will develop prototype instruments, participate in developing any testing protocols, provide clinical input with respect to current surgical procedures, provide evaluations of prototype products and test prototype and production products.  The assignment agreement assigned to the Company all this surgeon’s rights, title and interest in and to a U.S. patent application entitled Method For Coronary Artery Bypass.
Field of Use
The Field of Use apply to the medical device industry.

IPSCIO Record ID: 158782

License Grant
Pursuant to a prior employment agreement, the Licensor, of Japan and residing in the U.S. and the Licensee have a contractual agreement for patents.
License Property
The patents are for Contact Laser(TM) Probes and Scalpels and Contact Fibers, Heraeus LaserBlade(TM) Scalpels and Contact Fibers, HSI conical contact fibers.

'Contact Laser(TM) Patents' means the following three U.S. Patent Nos. 4,693,244; 4,592,353; and 4,736,743.

Field of Use
Licensee's Contact Laser(TM) System, unlike conventional laser systems, enables the surgeon to use the laser instrument in direct contact with the tissue being treated, thereby significantly enhancing the ease of use and precision of laser surgery in many applications.

IPSCIO Record ID: 375426

License Grant
The Licensee acquired certain intellectual property from an undisclosed Licensor to be used in the development of the ALLY Adaptive Cataract Treatment System.
License Property
ALLY Adaptive Cataract Treatment System is designed to combine our existing femtosecond laser technology with enhanced capabilities and a phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
Field of Use
The rights acquired are for laser technology in a device used by medical surgeons in a cataract procedure.

IPSCIO Record ID: 28946

License Grant
The Israel Licensors hereby grants to the Licensee the exclusive, royalty-bearing right and license in the Territory under the Licensee's Intellectual Property (including, for clarity, a sublicense under the Sublicensed IP) to Develop, Manufacture and Commercialize Products for use in the Field.
License Property
The Licensor owns or controls certain intellectual property rights covering a liquid polymer composed of Sodium Alginate and Ca-D-Gluconate (designated by BioLineRx as “BL-1040”).  The Licensor is currently developing the Product (as defined below) as a medical device for the direct treatment of cardiac tissue following acute myocardial infarction.

Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.

BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.

BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heart’s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.

Field of Use
The Licensee is developing BCM for the prevention of cardiac remodeling, which often leads to congestive heart failure following an ST-segment elevated myocardial infarction, or STEMI.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.